Cosmo announces placing of 4’250’000 Santarus shares in a secondary stock offering in USA Freitag, 10. Mai 2013 - 15:13

Lainate, Italy – May 10, 2013 – Cosmo Pharmaceuticals, (SIX:COPN) today announced that its subsidiary Cosmo Technologies Ltd, has placed 4’250’000 of its 7’878’544 Santarus (NASDAQ:SNTS) shares in a secondary underwritten public offering to investors in the USA at $ 18.25 per share. Cosmo Technologies granted Jefferies LLC, the underwriter, an option for thirty days to purchase up to 637’500 additional SNTS shares at the same price. Santarus did not sell any shares and will not receive any proceeds from the offering. The transaction is expected to close on May 15, subject to satisfaction of customary closing conditions. The shares were originally purchased at an average price of € 1.77. Per year end 2012 each share was worth € 8.32. After deduction of transaction fees & expenses a significant gain will be reported on the transaction.

About Cosmo Pharmaceuticals

Cosmo is a speciality pharmaceutical company that aims to become a global leader in the field of optimized therapies for selected Gastrointestinal and topically treated Skin Disorders. The company’s proprietary clinical development pipeline specifically addresses innovative treatments for IBD, such as Ulcerative Colitis and Crohn’s Disease, and Colon Infections. In addition, the Company is developing a diagnostic for the detection of colon cancer and a new chemical entity for the topical treatment of Acne, Alopecia and Hirsutism. Cosmo’s first product in the market is Lialda®/Mezavant®/Mesavancol®, a treatment for mild to moderate Ulcerative Colitis that is licensed globally to Giuliani and Shire Limited. Cosmo’s second product is Uceris™/Cortiment™, a steroid with low side effects that is indicated for Ulcerative Colitis patients that do not get relief when treated with 5-ASA’s and is licensed globally to Santarus and Ferring. Cosmo’s proprietary MMX® technology is at the core of the Company’s product pipeline and was developed from its expertise in formulating and manufacturing gastrointestinal drugs for international clients at its GMP (Good Manufacturing Practice) facilities in Lainate, Italy. The technology is designed to deliver active ingredients in a targeted manner in the intestines. For further information on Cosmo, please visit the Company’s website: www.cosmopharma.com

Contact: Cosmo Pharmaceuticals S.p.A.

Dr. Chris Tanner, CFO and Head of Investor Relations Tel: +39 02 9333 7614 ctanner@cosmopharma.com

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cosmo undertakes no obligation to publicly update or revise any forward-looking statements.